• Bio-Gate cut fiscal 2026 guidance on lower orders from two major customers amid portfolio changes, hitting Derma-Cosmetics and Wound Care.
• Revenue now seen at EUR 6.0 million to EUR 6.9 million, down from about EUR 6.9 million to EUR 7.9 million; prior year EUR 7.4 million.
• EBITDA forecast at minus EUR 0.9 million to minus EUR 1.1 million; prior year minus EUR 0.9 million, with cost cuts offsetting some impact.
• EBIT expected at minus EUR 1.1 million to minus EUR 1.5 million; prior year minus EUR 1.1 million.
• Implant coatings outlook unchanged; fiscal 2027 growth expected to resume with the two customers as new products and transitions roll out.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bio-Gate AG published the original content used to generate this news brief via EQS News (Ref. ID: adhoc_2411392_en) on October 06, 2026, and is solely responsible for the information contained therein.